Indacaterol: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PBAC (Australia) and PHARMAC (New Zealand), among others, recommended or restricted indacaterol, while CIPM (Spain) and CONITEC (Brazil) did not recommend it.
Assessment has run over 10.9 years, from 9 Aug 2010 at SMC (Scotland) to 8 Jul 2021 at CIPM (Spain).
No assessment is on file from AWMSG (Wales), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
Against its own class, indacaterol is an outlier: 67% of its decisive outcomes were positive, where molecules sharing ATC class R03A average 96%.
2 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess indacaterol, on 9 Aug 2010; CIPM (Spain) did not open a file until 8 Jul 2021 — an unusually long tail of 10.9 years between the earliest and latest system to look at it.
2 of the 6 agencies here assessed indacaterol more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for indacaterol.
The full ledger for indacaterol reads 4 recommended, 2 not recommended, 1 deferred and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 8 Jul 2021 | Indicación terapéutica autorizada: Tratamiento de mantenimiento del asma en adultos y adolescentes de 12 años de edad y … | not financed by the SNS · art. 92 c | source |
| PBAC (Australia) | 2020 | Asthma | The PBAC deferred making a recommendation for the listing of mometasone furoate (MF), with… | source |
| HAS (France) | 8 Feb 2017 | Listing renewal (Transparency Committee) | SMR substantial | source |
| CONITEC (Brazil) | 6 Mar 2013 | Tratamento da doença pulmonar obstrutiva crônica. | not incorporated | source |
| PHARMAC (New Zealand) | 16 Feb 2012 | Chronic obstructive pulmonary disease | PTAC advice: Cost Neutral · decision reached | source |
3 further decisions for indacaterol, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- budesonide / formoterol — same ATC class R03A — Obstructive airway diseases
- salbutamol — same ATC class R03A — Obstructive airway diseases
- formoterol — same ATC class R03A — Obstructive airway diseases
- terbutaline — same ATC class R03A — Obstructive airway diseases
- fluticasone / salmeterol — same ATC class R03A — Obstructive airway diseases
- olodaterol / tiotropium — same ATC class R03A — Obstructive airway diseases
Coverage: 8 decisions for indacaterol from 6 agencies, 2010 to 2021. Data to 7 Sep 2026. ATC class R03A — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.